![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis
Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting'
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
S Johnson1, H PariseAL1, Y Sanchez Gonzalez2, A Wang2, S Virabhak1, T Juday2, S Saab3
1Medicus Economics Inc., 2AbbVie, Inc., 3Pfleger Liver Institute, UCLA
![EASL1.gif](../images/042815/042815-11/EASL1.gif)
![EASL2.gif](../images/042815/042815-11/EASL2.gif)
![EASL3.gif](../images/042815/042815-11/EASL3.gif)
![EASL4.gif](../images/042815/042815-11/EASL4.gif)
![EASL5.gif](../images/042815/042815-11/EASL5.gif)
![EASL6.gif](../images/042815/042815-11/EASL6.gif)
![EASL7.gif](../images/042815/042815-11/EASL7.gif)
![EASL8.gif](../images/042815/042815-11/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|